Thoracic Oncology Internal Medicine Department 2

The Second Department of Thoracic Medical Oncology of Peking University Cancer Hospital focuses on lung cancer, malignant thymoma, pleural mesothelioma and other malignant tumours of the lung and thoracic cavity. It is a clinical department integrating care, teaching and research, with extensive clinical experience and advanced treatment concepts, and delivers individualised comprehensive care on a standardised basis. The department follows the latest international research and combines it with decades of clinical experience, always aiming to relieve patients' suffering and improve survival outcomes. It designs standardised, rational comprehensive treatment plans tailored to each patient, is experienced in the comprehensive treatment of all types of lung cancer, makes appropriate use of immunotherapy, targeted therapy, chemotherapy and other modalities, and works with thoracic surgery, radiation oncology and interventional radiology to provide whole-course management for cancer patients, including standardised management of cancer pain and other palliative care. It also provides bronchoscopic diagnosis and treatment and other procedures. The department has 29 beds. Over the years it has built a highly qualified and highly motivated patient-centred medical team and a well-trained, dedicated and caring nursing team. It has 37 medical and nursing staff in total, including 1 chief physician, 8 associate chief physicians, 4 attending physicians and 2 resident physicians. The head of the department, Fang Jian（方健）, is a chief physician and postgraduate supervisor who has been engaged in the medical management of lung cancer since 1989 and has studied at the renowned MD Anderson Cancer Center in the United States. He is currently vice president of the Beijing Cancer Prevention and Treatment Research Association and chair of its Lung Cancer Branch, vice chair of the Molecular Targeted Therapy Committee of the Geriatric Oncology Specialised Committee of the Chinese Gerontological Society, vice chair of the Precision Medicine and Oncology MDT Specialised Committee of the Chinese Research Hospital Association, vice chair of the Oncology Nutrition Specialised Committee of the China Anti-Aging Promotion Association, a member of the Lung Cancer Committee of the Geriatric Oncology Specialised Committee of the Chinese Gerontological Society, a member of the Non-Small Cell Lung Cancer Expert Committee of the Chinese Society of Clinical Oncology (CSCO), a member of the Vascular Targeted Therapy Expert Committee of CSCO, a member of the Thoracic Oncology Committee of the China International Exchange and Promotive Association for Medical and Health Care, an executive member of the Geriatrics Committee of the Chinese Anti-Cancer Association, and an expert drug reviewer for the National Medical Products Administration. In 2016 he received the second prize of the Huaxia Medical Science and Technology Award. He has led and taken part in numerous international and domestic multicentre clinical studies and has published dozens of papers. The department is currently conducting several international and domestic clinical research projects, including studies of novel chemotherapeutic agents, targeted agents and cancer therapeutic vaccines; the department's outpatient clinic provides related counselling.